Last reviewed · How we verify
Bumetanide white, oblong, scored tablet
Inhibits the Na-K-2Cl cotransporter 2 (NKCC2) in the thick ascending limb of the loop of Henle.
Inhibits the Na-K-2Cl cotransporter 2 (NKCC2) in the thick ascending limb of the loop of Henle. Used for Edema associated with congestive heart failure, cirrhosis of the liver, and a nephrotic syndrome in adults.
At a glance
| Generic name | Bumetanide white, oblong, scored tablet |
|---|---|
| Sponsor | B&A Therapeutics |
| Drug class | Loop diuretic |
| Target | Na-K-2Cl cotransporter 2 (NKCC2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
This action results in increased excretion of sodium, chloride, potassium, and water, leading to a decrease in blood volume and a subsequent decrease in blood pressure.
Approved indications
- Edema associated with congestive heart failure, cirrhosis of the liver, and a nephrotic syndrome in adults
Common side effects
- Hypokalemia
- Hyponatremia
- Dehydration
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bumetanide white, oblong, scored tablet CI brief — competitive landscape report
- Bumetanide white, oblong, scored tablet updates RSS · CI watch RSS
- B&A Therapeutics portfolio CI